Omega-3s Prescription Products: A Case Study of Innovation

September 10, 2012
Patricia Van Arnum

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Innovation is the cornerstone of the pharmaceutical industry.

Innovation is the cornerstone of the pharmaceutical industry. The challenge to innovation not only entails identifying drugs with clinical efficacy but also in being able to produce and deliver the desired drug compound. An upcoming Pharmaceutical Technology webcast, Omega-3 Innovations in Pharmaceutical and Diagnostic Markets, will examine the latest developments for omega-3 prescription drug products, their regulatory status, and recent advances in softgel drug-delivery technologies for omega-3 products.

The webcast will broadcast live on Sept. 11 from 10:00 AM EST to 11:15 AM EST with on-demand available following the broadcast. Omega-3s represent a small, but growing segment in the hyperlipidemia market. GlaxoSmithKline’s Lovaza is an example of strong-selling prescription omega-3 available in the United States. The webcast will examine the market opportunities for omega-3s in the hyperlipidemia market and other therapeutic areas as well, explain how monitoring one’s omega-3 index can improve health outcomes, and explore the latest advances in softgel drug-delivery technologies for highly purified omega-3 products.

Participating in the webcast are: Adam Ismail, executive director of the Global Organization for EPA and DHA Omega-3s (GOED); Dr. William Harris, research professor of medicine at the University of South Dakota and senior scientist, Health Diagnostics Laboratory; Irena McGuffy, manager, softgel formulation, Catalent Pharma Solutions; and David Fulper, director, technology support, Catalent Pharma Solutions.

Further details on the webcast, including registration details, may be found here.

Related Content:

PharmTech Talk